Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

USA - NASDAQ:QNRX - US74907L4095 - ADR

10.76 USD
-0.66 (-5.78%)
Last: 10/31/2025, 1:56:01 PM
Fundamental Rating

1

Overall QNRX gets a fundamental rating of 1 out of 10. We evaluated QNRX against 534 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QNRX has reported negative net income.
In the past year QNRX has reported a negative cash flow from operations.
In the past 5 years QNRX always reported negative net income.
QNRX had a negative operating cash flow in each of the past 5 years.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of QNRX (-136.54%) is worse than 83.71% of its industry peers.
QNRX's Return On Equity of -476.97% is on the low side compared to the rest of the industry. QNRX is outperformed by 76.97% of its industry peers.
Industry RankSector Rank
ROA -136.54%
ROE -476.97%
ROIC N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

QNRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for QNRX has been increased compared to 5 years ago.
QNRX has a better debt/assets ratio than last year.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

QNRX has an Altman-Z score of -13.35. This is a bad value and indicates that QNRX is not financially healthy and even has some risk of bankruptcy.
QNRX has a Altman-Z score of -13.35. This is in the lower half of the industry: QNRX underperforms 78.09% of its industry peers.
A Debt/Equity ratio of 1.03 is on the high side and indicates that QNRX has dependencies on debt financing.
The Debt to Equity ratio of QNRX (1.03) is worse than 76.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -13.35
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

QNRX has a Current Ratio of 1.95. This is a normal value and indicates that QNRX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of QNRX (1.95) is worse than 75.84% of its industry peers.
QNRX has a Quick Ratio of 1.95. This is a normal value and indicates that QNRX is financially healthy and should not expect problems in meeting its short term obligations.
QNRX's Quick ratio of 1.95 is on the low side compared to the rest of the industry. QNRX is outperformed by 73.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.57% over the past year.
EPS 1Y (TTM)78.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.76% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.43%
EPS Next 2Y34.39%
EPS Next 3Y23.36%
EPS Next 5Y20.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

QNRX's earnings are expected to grow with 23.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.39%
EPS Next 3Y23.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QNRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (10/31/2025, 1:56:01 PM)

10.76

-0.66 (-5.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners0.01%
Inst Owner Change0.14%
Ins Owners0.2%
Ins Owner Change1.03%
Market Cap6.33M
Revenue(TTM)N/A
Net Income(TTM)-12169300
Analysts82.5
Price Target28.05 (160.69%)
Short Float %14.86%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.93%
Min EPS beat(2)-5.04%
Max EPS beat(2)16.91%
EPS beat(4)3
Avg EPS beat(4)10.97%
Min EPS beat(4)-5.04%
Max EPS beat(4)25.4%
EPS beat(8)6
Avg EPS beat(8)9.96%
EPS beat(12)9
Avg EPS beat(12)12.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.23%
EPS NY rev (1m)0%
EPS NY rev (3m)29.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 2.99
EV/EBITDA N/A
EPS(TTM)-41.48
EYN/A
EPS(NY)-15.74
Fwd EYN/A
FCF(TTM)-18.18
FCFYN/A
OCF(TTM)-18.18
OCFYN/A
SpS0
BVpS4.34
TBVpS3.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.54%
ROE -476.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -13.35
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.99%
EPS Next Y73.43%
EPS Next 2Y34.39%
EPS Next 3Y23.36%
EPS Next 5Y20.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.58%
OCF growth 3YN/A
OCF growth 5YN/A

QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ

What is the ChartMill fundamental rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to QNRX.


What is the valuation status of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to QUOIN PHARMACEUTICALS LT-ADR (QNRX). This can be considered as Overvalued.


Can you provide the profitability details for QUOIN PHARMACEUTICALS LT-ADR?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a profitability rating of 0 / 10.


What is the financial health of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

The financial health rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1 / 10.